http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
-
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
-
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
-
Exscientia plc (EXAI) Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
-
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
-
Evotec Completes Acquisition of Central Glass Germany
-
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
-
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
-
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
-
Evotec SE (EVO) Enters Collaboration with Adapsyn
-
Adapsyn Bioscience enters into strategic collaboration with Evotec
-
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
-
Alpine Immune Sciences (ALPN) and Evotec (EVO) Expand Partnership for Development of ALPN-303
-
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
-
Exscientia plc (EXAI) Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
-
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
-
Evotec Enters a Drug Discovery Collaboration with Janssen
-
Evotec SE (EVO) and Almirall Enter Multi-Target Alliance in Medical Dermatology
-
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
-
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
-
Evotec SE (EVO) Announces EUR 7.5M Grant for Development of COVID-19 Therapeutic
-
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
-
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
-
Bitstarz - The first online casino to accept Bitcoin
-
Trustworthy live online Casino sites with Live Dealers UK

